Aimee R. Hayes
London, ENG NW32QG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Pancreatic neuroendocrine tumors in patients with tuberous sclerosis: a multicenter study and systematic review.
Journal: Journal of the Endocrine Society
Published: July 29, 2026
Impact of peptide receptor radionuclide therapy (PRRT) on the quality of life in patients with neuroendocrine tumours.
Journal: Journal of neuroendocrinology
Published: March 24, 2026
68Ga-DOTA-TATE PET/CT improves accuracy and guides management in multiple endocrine neoplasia type 1 (MEN-1) patients with suspected duodeno-pancreatic neuroendocrine tumours.
Journal: Endocrine oncology (Bristol, England)
Published: June 07, 2025
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence.
Journal: Endocrine oncology (Bristol, England)
Published: February 22, 2025
Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndrome.
Journal: Endocrine oncology (Bristol, England)
Published: February 14, 2025
Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas.
Journal: Endocrine oncology (Bristol, England)
Published: December 22, 2024
[18F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 19, 2024
Neuroendocrine tumours and pregnancy: Real-world data from an European Neuroendocrine Tumour Centre of Excellence.
Journal: Journal of neuroendocrinology
Published: June 10, 2024
Plasma or serum 5-hydroxyindoleacetic acid can be used interchangeably in patients with neuroendocrine tumours.
Journal: Scandinavian journal of clinical and laboratory investigation
Published: December 19, 2023
[18F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 17, 2023
Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score.
Journal: British journal of cancer
Published: April 04, 2022
Last Updated: 09/26/2026